Pfizer’s LITFULO cleared a major Phase 3 hurdle in vitiligo, but the missing numbers could decide its future
Pfizer’s Phase 3 LITFULO vitiligo results strengthen its filing case, but dose, safety and durability details remain decisive.
Pharma & Biotech
Pharma & Biotech
Incyte’s Opzelura wins positive CHMP opinion for moderate atopic dermatitis in Europe
The positive opinion moves ruxolitinib cream closer to a broader European label for adults inadequately controlled by standard topical therapies, opening a potential treatment position between conventional creams and systemic medicines.
Pharma & Biotech
Can Incyte’s 54-week povorcitinib data redefine the oral treatment landscape in hidradenitis suppurativa?
Incyte presents 54-week STOP-HS phase 3 data for povorcitinib at AAD 2026. Analyst review of durability, safety, and what the dataset means for the NDA.